AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel
Masahiro Yamamoto(Yamagata University), Masashi Okada(Yamagata University)
Cited by 19
Related Papers
Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
|Oncotarget|2014|74
The novel JNK inhibitor AS602801 inhibits cancer stem cells <i>in vitro</i> and <i>in vivo</i>
|Oncotarget|2016|59
Oncogenic Determination of a Broad Spectrum of Phenotypes of Hepatocyte-Derived Mouse Liver Tumors
|American Journal Of Pathology|2017|59
JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression
|International Journal of Oncology|2013|54